Literature DB >> 31819025

A de novo truncating mutation in ASXL1 associated with segmental overgrowth.

Stephanie Efthymiou1, Vincenzo Salpietro, Erica Pironti, Maria Bonsignore, Valentina Ferrazzoli, Gabriella Di Rosa, Henry Houlden.   

Abstract

Mutations in genes involved in chromatin remodelling have been implicated in broad phenotypes of congenital abnormalities and neurodevelopment. However, limited genotype-phenotype correlations are available for some of the rarest genetic disorders that affect chromatin regulation. We hereby describe a 12-year-old girl presented at birth with severe hypotonia, developmental delay, a mid-line capillary malformation and distinctive craniofacial features. During the natural history of her disease, the girl developed severe spasticity and drug-resistant seizures, leading to a diagnosis of Bohring-Opitz syndrome (BOS). We performed whole-exome sequencing (WES) and identified a de novo mutation in ASXL1 (c.2033dupG) which results in the introduction of a premature stop codon (p.R678fs*6). ASXL1 encodes a polycomb repressive complex protein implicated in chromatin regulation and de novo mutations are a known cause of BOS. Phenotypes with segmental craniofacial overgrowth associated to midline capillary malformations enlarge the clinical spectrum of BOS at onset and further expand the differential diagnosis in ASXL1 mutation carriers.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31819025      PMCID: PMC7116628     

Source DB:  PubMed          Journal:  J Genet        ISSN: 0022-1333            Impact factor:   1.166


  10 in total

1.  De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome.

Authors:  Alexander Hoischen; Bregje W M van Bon; Benjamín Rodríguez-Santiago; Christian Gilissen; Lisenka E L M Vissers; Petra de Vries; Irene Janssen; Bart van Lier; Rob Hastings; Sarah F Smithson; Ruth Newbury-Ecob; Susanne Kjaergaard; Judith Goodship; Ruth McGowan; Deborah Bartholdi; Anita Rauch; Maarit Peippo; Jan M Cobben; Dagmar Wieczorek; Gabriele Gillessen-Kaesbach; Joris A Veltman; Han G Brunner; Bert B B A de Vries
Journal:  Nat Genet       Date:  2011-06-26       Impact factor: 38.330

2.  A novel de-novo frameshift mutation of the ASXL1 gene in a classic case of Bohring-Opitz syndrome.

Authors:  Gautham Arunachal; Sumita Danda; Sabita Omprakash; Sathish Kumar
Journal:  Clin Dysmorphol       Date:  2016-07       Impact factor: 0.816

3.  Clinical management of patients with ASXL1 mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance.

Authors:  Bianca Russell; Jennifer J Johnston; Leslie G Biesecker; Nancy Kramer; Angela Pickart; William Rhead; Wen-Hann Tan; Catherine A Brownstein; L Kate Clarkson; Amy Dobson; Avi Z Rosenberg; Samantha A Schrier Vergano; Benjamin M Helm; Rachel E Harrison; John M Graham
Journal:  Am J Med Genet A       Date:  2015-04-29       Impact factor: 2.802

4.  Bohring-Opitz syndrome caused by an ASXL1 mutation inherited from a germline mosaic mother.

Authors:  Emma Bedoukian; Deborah Copenheaver; Sherri Bale; Matthew Deardorff
Journal:  Am J Med Genet A       Date:  2018-05       Impact factor: 2.802

5.  Two novel patients with Bohring-Opitz syndrome caused by de novo ASXL1 mutations.

Authors:  Pamela Magini; Matteo Della Monica; Maria Luisa Giovannucci Uzielli; Patrizia Mongelli; Gloria Scarselli; Eleonora Gambineri; Gioacchino Scarano; Marco Seri
Journal:  Am J Med Genet A       Date:  2012-03-14       Impact factor: 2.802

Review 6.  Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome.

Authors:  Colleen M Carlston; Anne H O'Donnell-Luria; Hunter R Underhill; Beryl B Cummings; Ben Weisburd; Eric V Minikel; Daniel P Birnbaum; Tatiana Tvrdik; Daniel G MacArthur; Rong Mao
Journal:  Hum Mutat       Date:  2017-03-21       Impact factor: 4.878

Review 7.  Bohring-Opitz syndrome (BOS) with a new ASXL1 pathogenic variant: Review of the most prevalent molecular and phenotypic features of the syndrome.

Authors:  Silvana Beatriz Dangiolo; Ashley Wilson; Vaidehi Jobanputra; Kwame Anyane-Yeboa
Journal:  Am J Med Genet A       Date:  2015-09-14       Impact factor: 2.802

8.  Screening of CD96 and ASXL1 in 11 patients with Opitz C or Bohring-Opitz syndromes.

Authors:  Roser Urreizti; Neus Roca-Ayats; Judith Trepat; Francisco Garcia-Garcia; Alejandro Aleman; Daniela Orteschi; Giuseppe Marangi; Giovanni Neri; John M Opitz; Joaquin Dopazo; Bru Cormand; Lluïsa Vilageliu; Susana Balcells; Daniel Grinberg
Journal:  Am J Med Genet A       Date:  2015-10-07       Impact factor: 2.802

9.  De Novo Mutations in PDE10A Cause Childhood-Onset Chorea with Bilateral Striatal Lesions.

Authors:  Niccolò E Mencacci; Erik-Jan Kamsteeg; Kosuke Nakashima; Lea R'Bibo; David S Lynch; Bettina Balint; Michèl A A P Willemsen; Matthew E Adams; Sarah Wiethoff; Kazunori Suzuki; Ceri H Davies; Joanne Ng; Esther Meyer; Liana Veneziano; Paola Giunti; Deborah Hughes; F Lucy Raymond; Miryam Carecchio; Giovanna Zorzi; Nardo Nardocci; Chiara Barzaghi; Barbara Garavaglia; Vincenzo Salpietro; John Hardy; Alan M Pittman; Henry Houlden; Manju A Kurian; Haruhide Kimura; Lisenka E L M Vissers; Nicholas W Wood; Kailash P Bhatia
Journal:  Am J Hum Genet       Date:  2016-04-07       Impact factor: 11.025

10.  Loss of Asxl1 Alters Self-Renewal and Cell Fate of Bone Marrow Stromal Cell, Leading to Bohring-Opitz-like Syndrome in Mice.

Authors:  Peng Zhang; Caihong Xing; Steven D Rhodes; Yongzheng He; Kai Deng; Zhaomin Li; Fuhong He; Caiying Zhu; Lihn Nguyen; Yuan Zhou; Shi Chen; Khalid S Mohammad; Theresa A Guise; Omar Abdel-Wahab; Mingjiang Xu; Qian-Fei Wang; Feng-Chun Yang
Journal:  Stem Cell Reports       Date:  2016-05-26       Impact factor: 7.765

  10 in total
  2 in total

Review 1.  Emerging multifaceted roles of BAP1 complexes in biological processes.

Authors:  Aileen Patricia Szczepanski; Lu Wang
Journal:  Cell Death Discov       Date:  2021-01-22

2.  Bohring-Opitz syndrome caused by a novel ASXL1 mutation (c.3762delT) in an IVF baby: A case report.

Authors:  Dongbo Wang; Xin Yuan; Haichun Guo; Shuyuan Yan; Guohong Wang; Yanling Wang; Tuanmei Wang; Jun He; Xiangwen Peng
Journal:  Medicine (Baltimore)       Date:  2022-02-04       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.